Press Release May 03 2021
Filed with NSE · · 2 pages · English
Summary by 6ix AI
The approval was granted by the Central Drugs Standard Control Organization in India for multiple strengths of the medication. NATCO plans to request a Compulsory License due to the public health emergency and aims to launch the product imminently.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from NATCO Pharma
- Press Release Apr 26 2021
- NATCO Pharma receives tentative approval for Ibrutinib tablets (generic for IMBRUVICA) ANDA in the US market
- Press Release Apr 10 2021
- NATCO Pharma forays into Pheromone based technology for Integrated Pest Management
- Press Release Mar 15 2021
Later from NATCO Pharma
- Press Release May 17 2021
- Press Release May 21 2021
- Press Release May 22 2021
- Press Release Jun 14 2021
- Press Release Jul 07 2021
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma